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Phosphoproteomic comparison of 
Pik3ca and Pten signalling identifies 
the nucleotidase NT5C as a novel 
AKT substrate
Larissa S. Moniz1, Silvia Surinova1, Essam Ghazaly2, Lorena Gonzalez Velasco1, Syed Haider2, 
Juan Carlos Rodríguez-Prados2, Inma M. Berenjeno1, Claude Chelala2 & Bart Vanhaesebroeck1
To identify novel effectors and processes regulated by PI3K pathway activation, we performed an 
unbiased phosphoproteomic screen comparing two common events of PI3K deregulation in cancer: 
oncogenic Pik3ca mutation (Pik3caH1047R) and deletion of Pten. Using mouse embryonic fibroblast (MEF) 
models that generate inducible, low-level pathway activation as observed in cancer, we quantified 7566 
unique phosphopeptides from 3279 proteins. A number of proteins were found to be differentially-
regulated by Pik3caH1047R and Pten loss, suggesting unique roles for these two events in processes such 
as vesicular trafficking, DNA damage repair and RNA splicing. We also identified novel PI3K effectors 
that were commonly-regulated, including putative AKT substrates. Validation of one of these hits, 
confirmed NT5C (5′,3′-Nucleotidase, Cytosolic) as a novel AKT substrate, with an unexpected role in 
actin cytoskeleton regulation via an interaction with the ARP2/3 complex. This study has produced a 
comprehensive data resource and identified a new link between PI3K pathway activation and actin 
regulation.
PI3K signalling is a major regulator of cell growth and metabolism and is one of the most frequently mutated 
pathways in cancer1–3. Two of the most common events are activating point mutations in the p110α isoform 
of PI3K (encoded by the PIK3CA gene), and loss-of-function of the lipid phosphatase and tumour suppressor 
PTEN4–6. Both of these events lead to elevated levels of the phosphatidylinositol(3,4,5)trisphosphate (PIP3) lipid, 
recruitment of PH domain-containing proteins to the plasma membrane and activation of effector proteins 
including AKT, mTOR and small GTPases such as Rac and RhoA7–10.
Despite activating the same pathway, mutations in Pik3ca and inactivation of PTEN are associated with 
overlapping but distinct tumour profiles and have different outcomes, both in the clinic and in mouse mod-
els of cancer6,11. Molecularly, Pik3ca mutant tumours are often dependent on p110α 12,13 while PTEN 
mutant tumours frequently require p110β activity14–16. There is also accumulating evidence that PTEN has 
phosphatase-independent functions in the nucleus that regulate genomic stability and may be important in 
tumourigenesis17.
While there are a number of PI3K pathway inhibitors in clinical trials, including p110α , AKT, mTOR and 
pan-PI3K inhibitors, they have so far shown limited efficacy1,18,19. This may be accounted for by the toxicity 
associated with complete inhibition of PI3K signalling, the existence of feedback mechanisms and the emergence 
of alternative pathways that can bypass PI3K pathway inhibition10. These obstacles highlight the importance of 
identifying novel players that may contribute to PI3K-driven cell growth.
To dissect the signalling mechanisms after Pik3ca mutation or Pten loss, we performed a phosphoproteomic 
screen using a label-free quantitative mass spectrometry method20. Label-free mass spectrometry is an alternative 
to label-based methods such as iTRAQ and SILAC, and has the benefit of allowing analyses of large numbers of 
samples as well as more consistent quantification of low abundance peptides21,22.
We were particularly interested in identifying molecular changes that occur at early time points after mutation 
and in response to low-level activation as these may most closely mimic physiological signalling events. Indeed, 
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in cancer, Pi3kca is activated from the endogenous locus and in the heterozygous state, and in the case of Pten, 
often by homozygous loss. We also aimed to assess the impact of Pi3kca activation/Pten loss at short time points 
after induction, in the absence of any other oncogenic mutations as well as in the absence of acute stimulation. 
This contrasts with other studies that examine the effect of PI3K activation in transformed cell lines, at long time 
points after mutation (when presumably other mutations have occurred) and/or in the presence of acute stimuli. 
In order to achieve these aims, we took advantage of two inducible genetic models of PI3K activation: primary 
mouse embryonic fibroblasts (MEFs) with heterozygous expression of the Pik3caH1047R hot-spot mutation from 
the endogenous locus or homozygous loss of Pten23. We generated phosphoproteomic profiles of Pik3caH1047R/WT, 
Ptenfl/fl and appropriate control MEFs.
Using this system we identified 7566 unique phosphopeptides from 3279 proteins. Analysis of regulated phos-
phopeptides identified events that were commonly regulated by both Pik3caH1047R and Pten loss as well as a num-
ber of cellular processes that were differentially-regulated by Pik3caH1047R expression or Pten loss. Validation of 
NT5C, one of the hits that was commonly-regulated by Pik3caH1047R and Pten loss, demonstrated that it is a novel 
AKT substrate as well identifying an unexpected role for this protein in regulating actin-dependent processes at 
the leading edge of the cell.
Results
Phosphoproteomic screen of oncogenic PI3K signalling. In order to map early molecular changes 
occurring upon PI3K pathway activation, we performed a phosphoproteomic screen using a label-free quanti-
tative mass spectrometry method20 on two 4-hydroxytamoxifen (4-OHT)-inducible primary MEF cell models: 
(1) heterozygous expression of the Pik3caH1047R hot-spot oncogenic mutation from the endogenous locus; fur-
ther referred to as Pik3caH1047R/WT cells, with wild-type control cells referred to as Pik3caWT/WT and (2) homozy-
gous loss of Pten23; further referred to as Ptenfl/fl, with wild-type control cells referred to as PtenWT/WT (Fig. 1a, 
Supplementary Fig. S1a). In all experiments, unless otherwise noted, MEFs were 4-OHT-treated.
The use of these two systems allowed us to compare and contrast the effects of two common modes of PI3K 
pathway activation which have overlapping but distinct effects both biochemically and clinically. To more faith-
fully mimic the physiologic effect of these genetic PI3K pathway alterations, we performed the screen under basal 
growth conditions (as opposed to in response to an acute external stimuli), and at short time points after induc-
tion (48 h for the Pik3caH1047R/WT screen and 96 h for the Ptenfl/fl screen; the later time point for the PTEN screen 
was chosen to allow degradation of the endogenous PTEN protein). Expression of either Pik3caH1047R/WT or loss 
of Pten resulted in a modest but sustained phosphorylation of downstream effectors including AKT, PRAS40, 
GSK3α /β and FKHR (Fig. 1a) as well as an enhanced ability of cells to form foci (Fig. 1b, Supplementary Fig. S1b).
Taking advantage of the fact that sample number is not a limiting factor in label-free quantitative mass 
spectrometry approaches, we used 4 independent MEFs per genotype, and repeated the experiment 3 times 
(Fig. 1c). We therefore analysed 12 samples per genotype for a total of 48 samples overall. This high level of 
Figure 1. Cellular models and phosphoproteomic workflow. (a) Western blot analysis of primary MEF 
lysates from a representative mass spectrometry experiment. Each lane represents an independent MEF line. 
(b) Focus formation assay of p53-immortalized MEFs of the indicated genotype. (c) Experimental design and 
workflow. Four individual MEF lines were used per genotype and the experiment was repeated 3 times.
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replication was selected to facilitate reproducible detection of small quantitative changes. Following a TiO2 
enrichment for phosphopeptides, samples were analysed by LC-MS/MS and peptides were identified and quan-
tified as previously described18,21. Strong quantitative reproducibility was achieved as measured by Pearson 
Correlation Coefficient which averaged r = 0.83 for experimental replicates and r = 0.87 for biological rep-
licates (Supplementary Table S1). In total we identified 9928 phosphorylation sites. There were 7566 unique 
phosphopeptides from 3279 proteins of which 78% were singly and 17% were doubly phosphorylated (Fig. 1c, 
Supplementary Table S2). Of the identified phosphorylation sites, 74% were on serine, 21% were on threonine and 
5% were on tyrosine (Fig. 1c). For further analysis, we modelled the data within MSstats statistical framework22. 
Peptides were included that were quantified in at least 6 out of 12 samples in at least one genotype (6970 peptides), 
and data were log2 transformed and quantile normalised (Supplementary Fig. S1c, Supplementary Table S3).
Identification of commonly- and differentially-regulated phosphopeptides. We defined a phos-
phopeptide to be regulated if changes in phosphorylation intensity (i.e. increases or decreases in phosphorylation) 
within a screen, or between the two screens, had a p-value of less than 0.05 (p < 0.05) (Supplementary Table S4). 
From the resulting analysis, there were i) 860 regulated phosphopeptides in the Pik3caH1047R/WT analysis, ii) 474 
regulated phosphopeptides in the Ptenfl/fl analysis and iii) 189 regulated phosphopeptides in the Pik3caH1047R/WT 
versus Ptenfl/fl comparison (Fig. 2a). In all three analyses the fraction of regulated sites with either enhanced or 
decreased phosphorylation was roughly 50%.
We were particularly interested in identifying phosphosites that had either the same or different patterns 
of regulation in Pik3caH1047R/WT or Ptenfl/fl cells, which we defined here as either “commonly-regulated” or 
“differentially-regulated”, respectively (Fig. 2a). Commonly-regulated peptides were defined as those that had a 
p-value < 0.05 in both the Pik3caH1047R/WT and the Ptenfl/fl analyses (Fig. 2b). Differentially-regulated peptides were 
those that had (1) a p-value < 0.05 in either the Pik3caH1047R/WT or the Ptenfl/fl analyses, and (2) a p-value < 0.05 
when comparing changes in phosphorylation intensity between the Pik3caH1047R/WT and the Ptenfl/fl screens 
(Fig. 2c). There were six peptides that were identified as being differentially-regulated as well being regulated in 
both the Pik3caH1047R/WT and the Ptenfl/fl screens (i.e. also commonly-regulated) and these were included in the 
differentially-regulated list.
Using these criteria, we identified 167 commonly-regulated phosphopeptides, including known 
PI3K-regulated sites such as Grb10 (pS500, pS501, pS503), Afadin (pS1795), and AAPK1 (pS496) (Fig. 2b, 
Supplementary Table S5). Further analysis indicated that all of the commonly-regulated peptides had changes 
in phosphorylation intensity that moved in the same direction in the two screens (i.e. enhanced or decreased 
phosphorylation in both screens). There was also a positive correlation (R2 = 0.92) between changes in phospho-
rylation intensity from the two screens, indicating that these peptides were in fact regulated in similar ways and 
are strong candidate PI3K effectors (Fig. 2b).
We also identified 150 phosphopeptides that were differentially-regulated in Pik3caH1047R/WT and Ptenfl/fl 
cells (Fig. 2c, Supplementary Table S6). In support of these phosphopeptides being regulated independently by 
Pik3caH1047R expression and loss of Pten, we did not observe any correlation (R2 = 0.05) between changes in phos-
phorylation between the two screens (Fig. 2c). The majority of these phosphopeptides were found to be regulated in 
only one of the screens while there was little to no change in phosphorylation seen in the other screen. There were 
6 differentially-regulated phosphopeptides that exhibited phosphorylation changes in both the Pik3caH1047R/WT 
and Ptenfl/fl screens. Four of these phosphorylation events (ARHGH (pS414), CETN2 (pS98), KIF1A (pT1528) 
and SRBS1 (pS1201)) were regulated in the same direction (i.e. upregulated in both screens or down-regulated 
in both screens), suggesting that they may in fact be commonly-regulated sites, differing only in the amplitude 
of their phosphorylation or the abundance of the total protein. However, there were two phosphosites, DNMT1 
(pS958) and EMSY (pT171) that were regulated in different directions, with increased phosphorylation in 
Pik3caH1047R/WT cells and decreased phosphorylation in the Ptenfl/fl screen. These proteins may represent a novel 
group of effector proteins that are regulated independently by different modes of PI3K activation.
To better understand the biological significance of these results, we used the functional annotation tool 
DAVID24 to identify biological processes that were enriched for proteins that contained regulated phospho-
rylation events. We compared the results from the commonly-regulated and differentially-regulated lists. 
Differentially-regulated peptides were analysed as both a single group and as separate categories of Pik3ca- or 
Pten-regulated proteins (Fig. 2d, Supplementary Tables S7 and 8). Proteins associated with the cytoskeleton were 
enriched in all categories, suggesting that this cellular component is very sensitive to alterations in PI3K signalling 
(Supplementary Table S9). Validating our approach, commonly-regulated proteins were enriched in processes 
and signalling pathways associated with PI3K activity, including receptor tyrosine kinase and insulin signalling, 
cellular metabolism and regulation of apoptosis. In addition, we observed enrichment in proteins associated with 
the mitochondria and the leading edge.
Analysis of differentially-regulated proteins (Fig. 2d) produced strikingly different results. Indeed, there 
was little overlap in the pathways that were enriched between the commonly and differentially-regulated hits. 
Processes that may be regulated differently by expression of Pik3caH1047R/WT or loss of Pten include those related to 
DNA organization and metabolism (including histone modification and DNA repair), and interestingly, proteins 
associated with cytoplasmic vesicles. Further analysis of differentially-regulated hits, highlighted some specificity, 
whereby Pik3caH1047R expression was associated with regulation of proteins localized to nuclear specks and the 
nuclear envelope, while Pten loss was predominantly associated with proteins involved with DNA metabolism 
and repair.
We also analysed the regulated phosphosites for overrepresented pSer motifs using the motif-x algorithm25,26 
which analyses the sequences that surround identified phosphorylation sites and identifies overrepresented 
motifs. Based on our knowledge of kinase consensus sequences we would hope to use the overrepresented motifs 
to identify key kinases that are regulated by Pik3caH1047R/WT or loss of Pten. Commonly-regulated phosphosites 
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Figure 2. Phosphoproteomic analysis of primary MEFs with inducible PI3K activation. (a) Venn diagram of 
regulated phosphopeptides (p < 0.05) in the three analyses i) Pik3caH1047R/WT (Pik3caH1047R/WT versus Pik3ca 
WT/WT); ii) Ptenfl/fl (Ptenfl/fl versus PtenWT/WT) and iii) Pik3caH1047R/WT versus Ptenfl/fl. (b) (left) Scatter plot 
of − log10 transformed p-values from Pik3caH1047R/WT and Ptenfl/fl analyses. A p-value < 0.05 (red line) 
was used to define commonly-regulated peptides (shaded in grey). Selected phosphorylation events are 
highlighted: previously identified PI3K-regulated sites (red dots), validated hit NT5C (blue dot). (right) 
Changes in phosphorylation intensity from commonly-regulated peptides in Pik3caH1047R/WT and Ptenfl/fl 
analyses. Coefficient of determination (R2) is shown. (c) (left) Plot of ranked − log10 transformed p-values 
from Pik3caH1047R/WT versus Ptenfl/fl analysis. Peptides with p-value < 0.05 are highlighted in grey. (middle) 
Phosphopeptides with p-value < 0.05 from Pik3caH1047R/WT versus Ptenfl/fl analysis were re-plotted according 
to their p-values from Pik3caH1047R/WT and Ptenfl/fl analyses. Peptides with p-value < 0.05 (red line) in 
either analyses were defined as differentially-regulated (highlighted in grey). Phosphopeptides that had a 
p-value < 0.05 in both the Pik3caH1047R/WT and Ptenfl/fl analyses are highlighted (yellow dots). (right) Changes 
in phosphorylation intensity from differentially-regulated peptides in the Pik3caH1047R/WT and Ptenfl/fl analyses. 
Coefficient of determination (R2) is shown. (d) Percentage of regulated hits enriched within cellular component 
or biological process categories (p < 0.05). Abbreviations used: RTK (Receptor Tyrosine Kinase); sig (signaling); 
R (Receptor); org/mod (organization/modification).
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were enriched in two motifs, RXXS and SP (Supplementary Fig. S2). RXXS is the consensus substrate motif for 
AGC kinases including PKA, p70S6K, SGK and AKT27. Since AKT preferentially phosphorylates an extended 
motif (RXRXXS)28, this indicates that PI3K activation regulates a number of AGC kinases in addition to AKT. 
Differentially-regulated phosphosites were also enriched for the SP motif (Supplementary Fig. S2). The relevance 
of this is unclear. Even though the majority of kinases strongly disfavour proline at position + 1, roughly 25% of 
identified phosphorylation sites in global phosphorylation studies are within SP or TP motifs. This suggests that 
proline-directed kinases such as GSK, CDK and ERK are more active, or have a larger number of substrates than 
other kinases29.
Finally, we used Scansite30 and PhosphoSitePlus® 31 to identify putative or known kinases for the regulated 
phosphorylation sites (Supplementary Tables S4 and 5). This analysis highlighted the broad effect that PI3K sig-
nalling has in cells, as we identified phosphorylation events that are predicted to be modulated by a number of 
different kinases including AKT, AMPK, CAMK2G, CDK5 GSK3 and PKA. Interestingly, we identified three 
differentially-regulated phosphorylation sites that either conform to the AKT consensus site (EMSY (pT171), 
ZNRF2 (pS75)) or is a known AKT site (NIBAN (pS601))32. In addition, we also found four previously unidenti-
fied AKT consensus sites on FA53B (pS168), K0284 (pS1166), NT5C (pS184) and PKHG3 (pS1134) which were 
commonly-regulated phosphorylation events.
Validation of NT5C as a novel AKT substrate. In order to validate our mass spectrometry screen we first 
confirmed the results on two phosphorylation sites for which commercially available antibodies were available, 
pS496 AAPK (peptide#3709) and pS1795 AFAD (peptide#0200). Both of these sites demonstrated enhanced 
phosphorylation phosphorylation in both Ptenfl/fl and Pik3caH1047R/WT cells compared to wild-type controls in 
both mass spectrometry screens and by immunoblotting (Fig. 3a,b).
Based on the potential biological relevance to PI3K-driven cell proliferation, we focused on NT5C (5′ ,3′ - 
Nucleotidase, Cytosolic) in order to further validate our mass spectrometry screen. NT5C, which demonstrated 
enhanced S184 phosphorylation in both Pik3caH1047R/WT and Ptenfl/fl cells (Fig. 3c,d, Supplementary Fig. S3a) is 
known to dephosphorylate monophosphorylated nucleotides, with an increased affinity for dNMPs33. While 
its’ in vivo role is largely uncharacterized, NT5C is predicted to act as a negative regulator of dNTP pools33,34. 
Based on this, our original hypothesis was that PI3K activation may increase cellular dNTP levels through 
phosphorylation-dependent inhibition of NT5C, ultimately supporting enhanced cell division.
We generated a phospho-specific antibody against phospho-S184 (α -pNT5C) (Supplementary Fig. S3b,c) and 
found elevated S184 phosphorylation in Pik3caH1047R/WT and Ptenfl/fl cells by western blot (Fig. 3e), consistent 
with the mass spectrometry results. Enhanced phosphorylation was observed at both short (2 days) and long (15 
days) time points after Pik3caH1047R/WT or Ptenfl/fl induction (Supplementary Fig. S3d,e). S184 is within a predicted 
AKT kinase consensus sequence, conserved in human and mouse and in NT5C’s closest homologue, the mito-
chondrial nucleotidase, NT5M (5′ ,3′ - Nucleotidase, Mitochondrial) (Fig. 3f). To formally test whether NT5C is 
an AKT substrate, we performed in vitro kinase assays using recombinant active AKT, and bacterially-produced 
GST-NT5C or the non-phosphorylatable mutant GST-NT5C S184A as substrate. Immunoblotting of these kinase 
reactions with α -pNT5C (Fig. 3g) or an antibody to phosphorylated AKT substrates (Supplementary Fig. S3f,g) 
demonstrated that AKT can phosphorylate NT5C on S184, and that this is the only AKT phosphorylation site 
on NT5C.
NT5C pS184 is sensitive to PI3K inhibition. We next examined how S184 phosphorylation on NT5C 
was regulated in cells, by testing its’ sensitivity to various inhibitors and stimuli. S184 phosphorylation was sen-
sitive to inhibition with the PI3K pathway inhibitors A66 (p110α inhibitor) and MK-2206 (AKT inhibitor), but 
not to rapamycin, U0126 or GSK-650394, which inhibit mTORC1, MEK1/2 and SGK1, respectively (Fig. 4a, 
Supplementary Fig. S4a). Interestingly, S184 phosphorylation was only sensitive to long-term (overnight) but 
not short-term (3 h) inhibition, whereas other PI3K-dependent phosphorylation sites, on effectors such as AKT 
and PRAS40, were inhibited at both time points (Fig. 4a). These results indicate that NT5C phosphorylation is 
regulated in a different manner than other previously established PI3K effectors such as AKT and PRAS40. For 
instance, while NT5C phosphorylation was sensitive to growth factor deprivation (Fig. 4b) and was enhanced by 
stimuli including FBS, EGF and insulin in an AKT-dependent manner (Fig. 4c), its kinetics of phosphorylation 
were delayed compared to AKT and PRAS40 (Supplementary Fig. S4b). Taken together, our data indicate that 
NT5C is phosphorylated on S184 in a PI3K-dependent manner, but that this event is not acutely regulated and 
might require sustained PI3K signalling.
Phosphorylation on S184 does not regulate NT5C catalytic activity. We were interested in deter-
mining the role of S184 phosphorylation in regulating NT5C function. Based on total levels of protein, S184 
phosphorylation did not appear to affect protein stability (Supplementary Fig. S5a). We next examined if S184 
phosphorylation regulated enzymatic activity by performing in vitro nucleotidase assays, using Flag-tagged NT5C 
constructs ectopically expressed in HEK293 cells. In line with previous reports33, wild-type NT5C, which is 
strongly phosphorylated on S184 in HEK293 cells (Supplementary Fig. S3f), demonstrated broad substrate speci-
ficity against monophosphorylated nucleotides (Supplementary Fig. S5b). NT5C displayed a preference for deox-
yribonucleotides over ribonucleotides, with the exception of UMP which was also a strong substrate for NT5C 
(Supplementary Fig. S5b). However, while a catalytically-inactive mutant (NT5C D12N) was unable to dephos-
phorylate nucleotides (Fig. 5a), we did not observe any difference in in vitro catalytic activity or substrate specificity 
between wild-type NT5C and the non-phosphorylatable NT5C S184A mutant (Fig. 5a). Therefore, based on these 
assays, we conclude that S184 phosphorylation is unlikely to regulate NT5C nucleotidase activity in vivo.
In order to test the in vivo role of NT5C, we used a mass spectrometry-based method to measure cellular con-
centrations of nucleotides. We first tested the hypothesis that PI3K signalling would increase cellular nucleotide 
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Figure 3. Validation of NT5C as a novel AKT substrate. (a) Fold change and p values for indicated 
phosphorylation sites. (b) Western blot validation of pS1795 AFAD and pS496 AAPK1. Ratio between 
phospho (p) and total protein is indicated. (c) Normalized log2 peak height intensities for NT5C peptide#5117 
(p5117), LLS^WSDNWR, containing S184. (d) NT5C amino acid sequence depicting trypsinization sites and 
quantified peptide highlighted in blue. Catalytic residue is highlighted in red and S184 phosphorylation site is 
highlighted in green. (e) Western blot analysis of NT5C pS184 from lysates used for mass spectrometry. Western 
blot panels from Fig. 1a have been reused. (f) Alignment of AKT substrate consensus site with NT5C and 
NT5M. (g) AKT in vitro kinase activity towards NT5C. Recombinant active AKT (200 ng) was incubated with 
bacterially produced NT5C (1 μ g). Phosphorylation was detected by immunoblotting with indicated antibodies. 
Quantification of 3 independent experiments, values are expressed relative to GST-NT5C without AKT. Error 
bars are sem, ***p < 0.001.
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pools by measuring NTP and dNTP levels in primary MEFs expressing Pik3caH1047R. We were unable to measure 
dGTP as it has the same mass and retention time as ATP which is 200 times more abundant than dGTP35. We 
observed a clear trend towards an increase of dCTP, dTTP and UTP, which was sensitive to A66 (p110α inhib-
itor) and to a lesser degree to MK-2206 (AKT inhibitor) (Fig. 5b). Based on our hypothesis, we predicted that 
loss of NT5C would mimic PI3K activation and lead to an increase in nucleotide pools. We first explored the 
impact of NT5C depletion on levels of dCTP for which we had seen the strongest effect of Pik3caH1047R expression. 
Surprisingly, knockdown of NT5C in either wild-type or Pik3caH1047R/WT cells had no apparent effect on the con-
centrations of dCTP (Fig. 5c) or other nucleotides tested (Supplementary Fig. S5c). These data suggest that NT5C 
does not play a major role in regulating nucleotide levels in this cellular system.
Figure 4. Regulation of NT5C S184 phosphorylation. (a) Sensitivity of S184 phosphorylation to PI3K 
pathway inhibitors. Primary MEFs were treated with A66 (3 μ M), MK-2206 (1 μ M), Rapamycin (20 nM), 
U0126 (10 μ M) or DMSO as control for 3 h or overnight (o/n) for 16–18 h before lysis. (left) Lysates were 
immunoblotted as indicated. (right) Quantification of 4 independent experiments. Values are expressed relative 
to DMSO treated Pik3caH1047R/WT cells. Error bars are sem, **p < 0.01. (b) Sensitivity of S184 phosphorylation to 
growth factor deprivation. Indicated primary MEFs were grown in 10% FBS or starved overnight in 0.1% FBS. 
(top) Lysates were immunoblotted as indicated. (bottom) Quantification of 5 independent experiments. Values 
are expressed relative to Pik3caH1047R/WT cells grown in 10% FBS. Error bars are sem, ***p < 0.001. (c) Sensitivity 
of S184 phosphorylation to growth factor stimulation. Primary MEFs were starved overnight in 0.1% FBS and 
stimulated with FBS (10%), Insulin (100 nM) or EGF (100 ng/ml) for the indicated times before lysis. DMSO or 
MK-2206 (1 μ M) was added at same time as stimuli. (top) Lysates were immunoblotted as indicated. (bottom) 
Quantification of 3–5 independent experiments. Values are expressed relative to time 0 for each stimuli. Error 
bars are sem.
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NT5C interacts with the ARP2/3 complex. We decided to explore whether NT5C might be involved in 
the regulation of other cellular processes in the context of PI3K signalling. Data from a high-throughput inter-
actome analysis36 had identified NT5C as an interacting partner of ARPC1B, a member of the ARP2/3 complex 
which nucleates branched actin assembly and is important for processes including cell migration and phagocy-
tosis37. To test this interaction, we immunoprecipitated Flag-tagged NT5C from cells and probed the immuno-
precipitates for ARPC1B. NT5C immunoprecipitates contained ARPC1B (Fig. 6a), validating the results from 
the interactome screen. In the same immunoprecipitates, we also detected the p34 protein, an integral member 
of the ARP2/3 complex (Fig. 6a). In the course of our experiments, we frequently observed a strikingly enhanced 
association between NT5C S184A and p34 or ARPC1B compared to NT5C WT (which is phosphorylated in 
both MEFs and NIH3T3 cells) or NT5C S184D (a putative phospho-mimetic mutant) (Fig. 6b). While this effect 
was often stronger in NIH3T3 cells than in MEFs, this indicates that phosphorylation at S184 may regulate the 
interaction between ARPC1B and NT5C.
We next examined the localization of NT5C in primary MEFs and in human HT1080 fibrosarcoma cells. 
The latter have large lamellipodia and have previously been used as a model cell system to study the ARP2/3 
complex38. In both cell types, Flag-NT5C was excluded from the nucleus and exhibited ubiquitous cytoplasmic 
Figure 5. Impact of S184 phosphorylation of NT5C catalytic activity. (a) S184 phosphorylation does not 
regulate NT5C nucleotidase activity in vitro. (left) Immunoprecipitates of Flag-NT5C ectopically expressed 
in HEK293 cells were incubated with 5 mM of the indicated nucleotides. Phosphate release was measured 
using a malachite green colorimetric assay and expressed as a percent of total nucleotide. The experiment 
was performed in duplicate and repeated 3 times independently. Error bars are sem. (right) Representative 
immunoblot from experimental cells. (b) Cells expressing Pik3caH1047R have elevated dNTP levels. (left, 
middle) Nucleotides were extracted from primary MEFs and analysed by UPLC-MS/MS. The experiment was 
performed in triplicate and repeated 4 times independently. Error bars are sem, *p < 0.05, **p < 0.01. (right) 
Representative immunoblot from experimental cells. (c) Effect of NT5C knockdown on cellular dCTP levels. 
(left) Nucleotides were extracted from primary MEFs, stably expressing indicated siRNA, and analysed by 
UPLC-MS/MS. The experiment was performed in triplicate and repeated 3 times independently. Error bars are 
sem. (right) Representative immunoblot from experimental cells.
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localization, with prominent staining at the cell edge (Fig. 6c,d, Supplementary Fig. S6a). Moreover, NT5C 
demonstrated partial colocalization with p34 at the cell edge (Fig. 6c,d) and with the actin-binding pro-
tein cortactin (Supplementary Fig. S6a) as well as limited colocalization with actin at the edge of the cell 
(Supplementary Fig. S6b). Similar patterns of localization were observed with NT5C S184A and NT5C S184D 
(Fig. 6c,d and Supplementary Fig. S6a,b).
NT5C regulates cell spreading. Based on the above data, that NT5C interacts with the ARP2/3 com-
plex and localizes to the cell edge, we explored a possible role for NT5C in regulating ARP2/3-dependent cell 
processes. We focused on two processes that are linked to ARP2/3 and lamellipodia formation, namely single 
Figure 6. NT5C interacts with the Arp2/3 complex. (a) NT5C immunoprecipitates with the ARPC1B and 
p34 proteins. Flag immunoprecipitates from primary MEFs stably expressing Flag-NT5C and indicated mutants 
were probed with indicated antibodies. (b) NT5C S184A exhibits enhanced binding to ARPC1B and p34. 
Immunoprecipitates from NIH3T3 cells stably expressing Flag-NT5C and indicated mutants were probed with 
indicated antibodies. Images cropped from single gel, denoted with black line. (c) NT5C localizes to cell edge 
and colocalizes with p34 in primary MEFs. Cells stably expressing Flag-NT5C constructs were fixed and stained 
with indicated antibodies. Cells were visualized by confocal microscopy (LSM Zeiss 700). Representative images 
are shown. (d) NT5C localizes to cell edge and colocalizes with p34 in HT1080 cells. Cells stably expressing 
hNT5C#1 siRNA and Flag-NT5C constructs were fixed and stained with indicated antibodies. Cells were 
visualized by confocal microscopy (LSM Zeiss 700). Representative images are shown.
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cell motility and cell spreading39. We first tested the effect on single cell motility of stable knockdown of NT5C 
in HT1080 cells, and found that depletion of NT5C caused a modest but significant decrease in distance trav-
elled per cell (Fig. 7a). This defect could be rescued by re-expression of wild-type NT5C (Fig. 7b). Expression of 
Figure 7. NT5C regulates cell motility and cell spreading. (a) NT5C regulates single cell motility. (left) 
HT1080 cells stably expressing siRNA were seeded into 96-well plates. Images were acquired every 10 min 
for 80 time points. Distance travelled is expressed relative to siControl cells. The experiment was repeated 3 
times independently. n = 235–301 cells per cell line; Error bars are sem; ***p < 0.001. (right) Representative 
immunoblot from experimental cells. (b) NT5C expression rescues motility defect. HT1080 cells stably 
expressing siRNA and Flag-NT5C rescue constructs were processed as in (a). Analysis of distance travelled 
is expressed relative to cells expressing Control siRNA and empty vector cDNA. The experiment was 
repeated 4 times independently. n = 138–472 cells per cell line. Error bars are sem; *p < 0.05, **p < 0.01. (c) 
NT5C regulates single cell spreading. HT1080 cells stably expressing siRNA were trypsinized, seeded onto 
fibronectin coated plates and fixed at 45 min post-seeding. (left) Cell area was determined manually in ImageJ 
and is expressed relative to siControl cells. The experiment was repeated 3 times independently. n = 326–431 
cells per cell line; Error bars are sem; *p < 0.05, **p < 0.01. (top right) Representative image. (bottom right) 
Representative immunoblot from experimental cells. (d) NT5C expression rescues spreading defect. (top) 
HT1080 cells stably expressing siRNA and Flag-NT5C rescue constructs were processed as in (c). Cell spreading 
is expressed relative to cells expressing Control siRNA and empty vector cDNA. The experiment was repeated 
4 times independently. n = 555–659 cells per cell line; Error bars are sem; *p < 0.05, **p < 0.01, ***p < 0.001. 
(bottom) Representative immunoblot from experimental cells. (e) NT5C knockdown impairs cell spreading in 
primary MEFs. Primary MEFs stably expressing siRNA were processed as in (c) 96 h after 4-OHT treatment. 
(left) Cell spreading is expressed relative to Pik3caWT/WT cells expressing Control siRNA. The experiment 
was repeated 3 times independently. n = 244–356 cells per cell line; Error bars are sem; **p < 0.01. (right) 
Representative immunoblot from experimental cells.
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NT5C S184A led to a partial rescue of the motility defect, whereas NT5C S184D was unable to rescue the defect 
(Fig. 7b).
We next asked if NT5C was involved in cell spreading, a process that is positively regulated by ARP2/339, by 
measuring cell area 45 min after cells were plated on fibronectin. Knockdown of NT5C inhibited cell spreading 
(Fig. 7c) and this was rescued by stable expression of wild-type NT5C (Fig. 7d). Expression of NT5C S184A was 
unable to rescue the defect while NT5C S184D expression caused a partial rescue (Fig. 7d). Finally, we exam-
ined if NT5C could regulate PI3K-dependent cell spreading. Primary MEFs expressing Pik3caH1047R exhibited 
a slightly enhanced ability to spread following plating on fibronectin, compared to 4-OHT-treated control cells 
(Fig. 7e). This process was partially inhibited by knockdown of NT5C in Pik3caH1047R/WT cells and more strikingly 
in Pik3caWT/WT cells (Fig. 7e).
Taken together, our phoshoproteomic screen provides an insight into the complex signalling governed by two 
common cancer-causing mutations in the PI3K pathway. Our validation of one of these targets has identified 
NT5C as a novel AKT substrate, and reveals an unexpected role for this protein in ARP2/3-regulated processes 
such as cell spreading and motility.
Discussion
PI3K signalling is one of the most frequently activated pathways in cancer. While both Pik3caH1047R expression 
and loss of function of PTEN enhance PIP3 lipid levels and lead to AKT activation, their effect on tumour devel-
opment both in mouse models and in the clinic displays distinct latency, spectrum and sensitivity to chemo-
therapy11,40,41. We were interested in understanding the molecular changes caused by these two genetic modes of 
PI3K pathway activation and, to our knowledge, our study is the first comprehensive phosphoproteomic analysis 
comparing and contrasting these two prevalent cancer-promoting events.
We used a label-free quantitative mass spectrometry method to obtain unbiased phosphoproteomic profiles 
from primary MEFs, which either heterozygously express the endogenous Pik3caH1047R mutant allele or have 
homozygous loss of Pten. The aim of our screen was to faithfully mimic mutational activation of the PI3K path-
way as observed in cancer. Indeed, in cancer, Pi3kca is activated from the endogenous locus and in the heterozy-
gous state, and in the case of Pten, often by homozygous loss. In addition, we attempted to model the effects of 
Pi3kca activation/Pten loss at short time points after induction and in the absence of acute stimulation. This con-
trasts with other studies that examine the effect of PI3K activation in transformed cell lines, at long time points 
after mutation (when presumably other mutations have occurred) and/or in the presence of acute stimuli. As far 
as we are aware, such analysis of low level PI3K pathway activation as observed in cancer has not been carried 
out to date.
Using this system, we identified 7566 unique phosphopeptides from 3279 proteins, with 860 and 474 phos-
phopeptides regulated in the Pik3caH1047R and Ptenfl/fl screens, respectively. It is important to note that as samples 
were collected 48–96 h after mutation induction our screen is not restricted to acute effects of PI3K activation 
but may also reflect secondary effects which could rely on transcription or translation of regulating proteins or 
could be caused by changes in target protein abundance. The two categories of phosphorylation events that we 
were particularly interested in were those that were either commonly- or differentially-regulated between the 
Pik3caH1047R and Ptenfl/fl screens. In the category of commonly-regulated phosphopeptides, we identified 167 
peptides. These included a number of known PI3K-regulated phosphorylation sites, such as on GRB10, GRB14, 
Afadin and AMPKα , as well as novel putative substrates of GSK3 and AKT, one of which, NT5C, we characterized 
in more detail.
We also identified 150 peptides that had markedly different changes in phosphorylation intensity between the 
two screens. Two of these, DNMT1 (pS958) and EMSY (pT171), were regulated in both genetic contexts, with 
enhanced phosphorylation in Pik3caH1047R cells and decreased phosphorylation in Ptenfl/fl cells. The identified site 
on DNMT1 (DNA (cytosine-5)-methyltransferase 1), pS958, is within a high stringency CDK5 consensus site. 
Intriguingly, DNMT1 is a known negative regulator of Pten transcription and is upregulated in some cancers42,43. 
Our mass spectrometric result suggests there might be reciprocal regulation or feedback from PTEN to DNMT1. 
EMSY (BRCA2-interacting transcriptional repressor EMSY) localizes to sites of DNA repair and acts as a repres-
sor of BRCA2 transactivation44. Unexpectedly, not only is T171 within a high stringency AKT consensus site but 
S173, which is also within the identified peptide, has been previously shown to be phosphorylated by AKT1 and 
to be important for the interferon response45. At present, it is not clear how an AKT substrate could be so differ-
ently regulated by Pik3caH1047R compared to Pten loss.
Functional annotation of the regulated proteins revealed some further trends. Firstly, we observed that all 
groups of regulated peptides were enriched for functions related to the cytoskeleton. This is in agreement with 
a previous phosphoproteomic screen which identified a strong link between oncogenic Pik3ca mutation and 
cytoskeleton rearrangement and cell migration46. More specifically, we identified an enrichment of proteins 
located at the cell cortex and cell edge. This was further supported by our unexpected finding that NT5C also 
localizes to this cellular compartment.
Our study also identified some processes that may be differentially-regulated downstream of Pik3ca and Pten. 
Firstly, there was enrichment of proteins associated with the nuclear envelope (i.e. LMNB1, NU214) and nuclear 
specks (i.e. PRPF3, SRRM1) specifically in response to Pik3caH1047R activation, indicative of a specific role for 
p110α signalling in nuclear transport and mRNA splicing. In support of a putative p110α -specific effect in the 
nucleus, there is evidence that a nuclear pool of PIP3 exists, that is associated with nuclear specks and is insensitive 
to PTEN47. Secondly, PTEN loss was associated with enrichment in proteins associated with DNA modification, 
organization and repair, including the centromeric protein INCE and NBN which is mutated in the chromosomal 
instability syndrome, Nijmegen breakage syndrome48. These data are consistent with previously-documented 
phosphatase-independent roles of PTEN in regulating genome stability49 and may identify additional players 
involved in this process. Finally, we identified vesicular processes, associated with proteins such as SYTL4 and 
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SNTB2, as being divergently regulated by Pik3caH1047R and Pten loss. As phosphoinositide conversion plays an inte-
gral role in vesicular trafficking, it is tempting to speculate that gain-of-function of a phosphoinositide kinase (p110α ) 
could have different effects on the composition of phosphoinositide lipid species compared to loss-of-function of 
the lipid phosphatase PTEN. Taken together, the data from our phosphoproteomic analysis supports further study 
of the role and importance of subcellular pools of phosphoinositides in diverse cellular processes.
In order to validate our mass spectrometric screen, we focused on NT5C (5′ ,3′ - Nucleotidase, Cytosolic). 
NT5C p184 was a commonly-regulated phosphorylation event, elevated in both Pik3caH1047R/WT and Ptenfl/fl cells, 
and is within an AKT substrate consensus site. Using a phospho-specific antibody we confirmed the mass spec-
trometric result and demonstrated that S184 in NT5C was phosphorylated by AKT in vitro and was sensitive to 
PI3K inhibitors in cells. Therefore we conclude that NT5C is a novel AKT substrate. However we do not discount 
the possibility that other PI3K-activated AGC kinases, such as SGK3, may also phosphorylate this S184 in a 
cell- or context-dependent manner. Despite being sensitive to PI3K inhibition, S184 phosphorylation displayed 
strikingly different kinetics than other known PI3K effectors such as AKT or PRAS40, in that phosphorylation 
and dephosphorylation did not appear to be acutely regulated, but instead occurred only after long-term stimu-
lation or inhibition, respectively. Based on this, we speculate that S184 phosphorylation may not be subject to a 
constitutively active phosphatase and/or may require additional post-translational modifications to occur.
Contrary to our original hypothesis, S184 phosphorylation did not have an impact on NT5C catalytic activity. 
Even more surprising, while we observed elevated pools of dNTPs in Pik3caH1047R-expressing cells, they were not 
sensitive to NT5C depletion. A caveat with these results is that we were unable to achieve complete knockdown 
of NT5C by siRNA and the remaining protein may be sufficient to perform its nucleotidase function. However, 
although contrary to expectations, we propose that NT5C may not be the major 5′ 3′ -nucleotidase activity in the 
cell. In support of this, data from publically available databases show a frequent amplification of NT5C in can-
cer, at both the transcript and protein level50,51. We also observed elevated NT5C levels in transformed cell lines 
compared to non-transformed cell lines such as NIH3T3 and primary MEFs (data not shown). This expression 
pattern appears counter-intuitive if NT5C was a major negative regulator of nucleotide synthesis, as NT5C over-
expression would presumably decrease dNTP pools in cells which have enhanced proliferation rates and thus 
require elevated nucleotide levels.
Data from an interaction database36 prompted us to explore a role for NT5C in regulating the actin cytoskel-
eton. Our data indicate that NT5C interacts with the ARP2/3 complex, in a manner that may be dependent on 
S184 phosphorylation of NT5C. A role for NT5C S184 phosphorylation in mediating an interaction with the 
ARP2/3 complex, is supported by our cell-based studies, where only wild-type NT5C was able to fully rescue 
the motility and spreading defects caused by NT5C depletion. These defects were modest, suggesting that NT5C 
is not essential for these processes, but may instead play a regulatory role by modulating the amplitude of the 
cell’s motility response. The partial rescue by NT5C S184A and NT5C S184D may be indicative of the variable 
results we had dissecting the Arp2/3 interaction. Of note, particularly in the cell spreading assay, neither NT5C 
S184A nor NT5C S184D were able to fully rescue the effect of NT5C knockdown. This could suggest the need for 
dynamic regulation of the phosphorylation site that occurs in a location-specific manner. Based on these results 
we hypothesize that the NT5C-Arp2/3 interaction regulates Arp2/3 complex activity at the cell edge and that this 
interaction modulates processes such as lamellipodia formation, cell spreading and cell motility. How exactly 
NT5C may effect Arp2/3 activity and actin dynamics remains a question for future study.
Taken together, we have produced an unbiased resource of two models of PI3K-regulated phosphorylation. 
Validation of one of the hits from the screen has identified NT5C as a novel AKT substrate, and point towards an 
underexplored role for PI3K in regulating actin dynamics at the cell edge. Future work will be important to more 
fully dissect the interaction between NT5C and the Arp2/3 complex and its role in PI3K-regulated cell motility. 
Our study adds to the growing realization that PI3K pathway activation in cells leads to an extensive remodelling 
of the transcriptome and proteome46,52–54, a phenotype referred to as a ‘butterfly effect’53,55.
Methods
Mutant Mice and Mouse Embryonic Fibroblasts (MEFs) Derived Thereof. Mice were housed in 
individually-ventilated cages and cared for in accordance with UK Home Office guidelines and legislation, with 
procedures approved by the Ethics Committees of University College London and Queen Mary University of 
London. Pik3caH1047R+neo/WT is a mouse line in which one of the two wild-type (WT) Pik3ca alleles is converted 
to Pik3caH1047R. Due to the presence of a neomycin (Neo) selection cassette in the targeted Pik3ca locus, the 
expression of the mutant p110α H1047R protein is dampened, resulting in minimal or no activation of the PI3K 
pathway. Pik3caH1047R+neo mice were crossed with CAG::Flpe-ERT2 mice56 that express a germline Flp recom-
binase that is inducible by 4-OHT. Pik3caH1047R/WT; FlpER(T2)+/− mice are further referred to as Pik3caH1047R/
WT mice. 4-OHT treatment resulted in the removal of Neo cassette, restoration of p110α H1047R expression 
levels to those of endogenous p110α WT and PI3K pathway activation. The presence of the Pik3caH1047R+neo 
mutant allele was monitored by PCR using neo cassette primers: 5′ -GGTTCCAGCCTGAATAAAGCC-3′ and 
5′ -AGATCAGCAGCCTCTGTTCC-3′ , giving rise to an expected PCR fragment of 307 bp. In each amplifi-
cation cycle, denaturation was performed for 30 sec at 95 °C, annealing for 30 sec at 60 °C, and extension for 
1 min at 72 °C; the number of cycles was 35 followed by a final extension of 10 min at 72 °C. Following Flp-
mediated recombination the presence of the recombined allele was monitored using recombination primers: 
5′ -GGTTCCAGCCTGAATAAAGCC-3′ and 5′ -CACAGCTGTCCTGGGTAAGG-3′ and the same PCR condi-
tions described above where used. The size of the expected PCR fragments was 425 bp (recombined mutant 
allele) or 340 bp (wild-type locus). The PTENfl mouse line in which exon 5 in the phosphatase domain of PTEN is 
flanked by loxP recombination sites, has been described23. These mice were crossed onto CreER(T2)+/− mice that 
express a germline 4-OHT-inducible Cre57, generating Ptenfl/flCreER(T2)+/− mice, further referred to as Ptenfl/fl 
mice. MEFs made from E13.5 embryos were treated with 1 μ M 4-OHT for one or two consecutive days. Unless 
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mentioned, all experiments with primary MEFs were performed 48–96 h post 4-OHT treatment; control cells 
were also treated with 4-OHT. Efficiency of recombination was assessed by PCR or western blot analysis.
Cell Culture. HT1080 cells were cultured in DMEM, high glucose, GlutaMAX™ Supplement (Invitrogen 
#61965–026) with 10% FBS and penicillin-streptomycin. All other cells were cultured in DMEM with 10% FBS 
and penicillin-streptomycin. For phosphoproteomic experiments primary MEFs were grown under normoxic 
conditions. For all other experiments, primary MEFs were grown under hypoxic conditions (5% CO2, 3% O2) 
which increases the proliferative lifespan of cultured cells58.
Western blot analysis and antibodies. Whole-cell lysates or immunoprecipitates were resolved by 
SDS-PAGE and blotted onto polyvinylidene difluoride (PVDF) membranes. Proteins were probed using pri-
mary antibodies obtained from the following sources (catalog number between brackets): pAKT (S473) (#9271), 
pAKT (T308) (#4056), AKT (#9272), pERK1/2 (T202/Y204) (#9106), p110α (#4249), PTEN (#9552), pFoxO1/3a 
(T24/T32) (#9464), pGSK3 (S21/9) (#9331), pS6 (S240/4) (#2215), pp70S6K (T389) (#9205), pPRAS40 (T246) 
(#2640), pNDRG1 (T346) (#3217), pAFAD (S1718) (#5485), pAAPK1 (S485) (#2537), AMPK (#2532) and GST 
(#2624) from Cell Signaling Technology; ARPC1B (#HPA004832), Vinculin (#V9131) and Flag M2 (#F3165) 
from Sigma; NT5C (#NBP1-84563) from Novus Biologicals; p34 (#07-227) from Millipore and AFAD (ab90809) 
from Abcam. A rabbit affinity-purified polyclonal antibody against NT5C pS184 (mouse NT5C amino acid 
numbering, equivalent to human NT5C pS182) was developed in collaboration with GenScript, utilizing the 
RLLpSWSDNWREILDC peptide, covering amino acids 179–192 of human NT5C. Quantification of western 
blots was performed using ImageJ.
Focus Formation Assay. Primary MEFs were immortalized by stable transfection of p53 siRNA59. 
4-OHT-treated p53-immortalized MEFs were grown to confluence and maintained for 13 days, with regular 
changes of culture media. Plates were fixed in 3.7% formaldehyde and stained with 0.1% crystal violet followed 
by extensive washing in water.
Mass Spectrometry-Based Phosphoproteomics. Samples were processed as described60, with the fol-
lowing modifications. Primary MEFs were lysed 48 or 96 h after 4-OHT treatment in 1 ml of urea buffer per 
15 cm tissue culture dish. Reduction and alkylation of cysteines was performed at room temperature for 15 min 
in the dark. For TiO2 enrichment of phosphopeptides, packed tips were sequentially washed with glycolic acid 
buffer 2, 99/1 H2O/ACN and eluted with four sequential washes of 5% NH4OH in 1% ACN. LC-MS/MS analysis 
and data processing was performed as described61. Briefly, phosphopeptide pellets were resuspended in 20 μ l of 
0.1% TFA, and 4 μ l was loaded into an LC-MS/MS system, which consists of a nanoflow ultrahigh pressure liquid 
chromatography (UPLC, nanoAccuity, Waters) coupled online to an Orbitrap XL mass spectrometer (Thermo 
Fisher Scientific). The top five most intense multiply charged ions were selected for collision-induced dissociation 
fragmentation in multistage activation mode. The resolution of MS1 was set to 60,000.
Peptide Identification and Quantification. Peptide identification was performed by searching the MS/
MS data against the SwissProt database restricted to mouse entries with the Mascot search engine62. Mass toler-
ances were set to 10 parts per million (ppm) and 600 millimass units for parent and fragment ions, respectively. 
Allowed variable modifications were phosphorylation on Ser, Thr, and Tyr; PyroGlu on N-terminal glutamine; 
and oxidation of methionine. Phosphopeptides with a Mascot expectancy of < 0.05 (~2% false discovery rate) 
were included in a database of sites quantifiable by MS. Pescal software63 was then used to obtain peak heights of 
extracted ion chromatograms of phosphorylated peptides in this database across all the samples being compared. 
Pescal aligned retention times using those of peptides common to all samples as reference points along chroma-
tograms. The extracted ion chromatogram (XIC) windows were 6 ppm and 2 min. Accuracy of phosphorylation 
site identification is expressed by the max_delta score (Supplementary Table S2).
Statistical and Functional Analysis of the Phosphoproteomic Data Set. Quantified phosphopep-
tides were analysed within the model-based statistical framework MSstats v3.3.164. The experimental design was 
defined by two screens and two conditions per screen. Each condition was replicated three times experimentally 
and four times biologically. For statistical analysis, peptides were included if they were quantified in at least 6 out 
of 12 samples in at least one genotype. The data was log2 transformed and quantile normalised. To find differ-
ential abundant proteins across conditions, significance analysis consisting of fitting a statistical model and per-
forming model-based comparison of conditions was performed within MSstats. The group comparison function 
was employed to test for differential abundance between conditions or screens. Unadjusted p-values were used 
to rank the testing results and to define regulated phosphopeptides within and between screens. The DAVID 
Bioinformatics Resource (https://david.ncifcrf.gov/summary.jsp) was used to perform functional annotation of 
regulated peptides, using the complete list of peptides identified within our mass spectrometric screen as back-
ground. Categories/Processes were enriched if they had a p-value < 0.05. The motif-x algorithm (http://motif-x.
med.harvard.edu) was used to extend and extract motifs25,26. The significance threshold was set to p-value < 1e− 
3, minimum occurrence of motif was 20 for pSer peptides using an IPI Mouse proteome background. We used 
Scansite30 (http://scansite.mit.edu/) to identify predicted kinases and PhosphoSitePlus® (http://www.phosphosite.
org/)31 to identify previously validated kinases for identified phosphorylation sites at high stringency.
Plasmids, Cloning and Cellular Knock-down of NT5C. NT5C cDNA was amplified from a 
mouse cDNA library using the following primers [Forward (with added EcoRI restriction site, underlined) 
5′ -TACGCGAATTCAATGGCGGTGAAGCGGCCCGT-3′ ; Reverse (with added XbaI restriction site) 
5′ -ATCCTCTAGATCACAGGCTGGCTCGCTTGC-3′ ], cloned into the EcoRI and XbaI restriction sites within 
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the multicloning site of 3xFlag-CMV-7.1 and fully sequenced. NT5C was then subcloned into pGEX4T3 and 
sequenced. Lentiviral plasmids were constructed using the Gateway system as follows: Flag-NT5C was sub-
cloned into the entry vector pEntr1A, sequenced, following by cloning through recombination into the destina-
tion vector pLenti CMV Blast Dest (Addgene#17451). Point mutants of NT5C were generated by site-directed 
mutagenesis and sequenced. For transient knockdown of NT5C in human cells, ON-TARGET plus Human 
NT5C (30833) siRNA-SMART Pool was purchased from ThermoScientific (L-020511-01-0005). For stable 
knockdown of NT5C, shRNAmir were purchased from Open Biosystems as follows: non-silencing scrambled 
(ATCTCGCTTGGGCGAGAGTAAG), shRNAmir against mouse NT5C: NT5C#1 (V2LMM_33051), NT5C#2 
(V3LMM_521869), shRNAmir against human NT5C: hNT5C#1 (V2LHS_85392), hNT5C#2 (V2LHS_85394).
Cell Lysis and Immunoprecipitation. Cells were lysed in CHAPS lysis buffer (40 mM HEPES [pH 7.5], 
0.5% CHAPS, 120 mM NaCl, 1 mM EDTA, containing 1 mM DTT, phosphatase (phosSTOP (Roche)) and pro-
tease (Sigma) inhibitor cocktails). For analysis of protein interaction, anti-Flag M2-agarose immunoprecipitations 
were performed overnight at 4 °C. All other immunoprecipitations were performed with anti-Flag M2-agarose 
or glutathione-Sepharose 4 Fast Flow (GE Healthcare) for 2 h at 4 °C, washed four times with CHAPS lysis buffer 
and eluted by boiling in sample buffer.
AKT Kinase Assay. Kinase assays were performed in a 30 μ l reaction mixture containing active 250 ng AKT 
(purchased from Millipore) and bacterially produced GST-tagged NT5C proteins (1 μ g) in kinase assay buffer 
(10 mM MOPS, pH 7.2, 20 mM MgCl2, 2.5 mM EGTA, 12.5 mM β -glycerol phosphate, 0.5 mM sodium orthov-
anadate, 0.5 mM dithiothreitol (DTT)). Kinase assays were initiated by addition of 80 μ M ATP and performed 
for 30 min at 30 °C. Reactions were stopped by addition SDS-PAGE sample buffer, separated by SDS-PAGE and 
phosphorylation detected by immunoblotting.
NT5C Enzymatic Assay. Flag-NT5C immunoprecipitates were washed two times in CHAPS lysis buffer and 
two times with Phosphatase reaction buffer (20 mM MgCl2, 50 mM Tris-maleate, pH 6.0, 0.2 mg/ml bovine serum 
albumin, 5 mM DTT). Phosphatase assays were performed in a 50 μ l reaction containing 5 mM of nucleotide sub-
strate in phosphatase reaction buffer. Reactions were carried out for 30 min at 37 °C. Reactions were stopped by 
addition of 200 μ l dH2O, centrifuged and placed on ice. Supernatant containing released phosphate was measured 
using a malachite green-based colorimetric phosphate assay kit (Abcam #ab65622), according to the manufactur-
er’s instructions. Experiments were performed in duplicate and results averaged.
Preparation of Lentivirus and Lentiviral Transduction. shRNAmir lentivirus was produced and 
titrated by the Genomics Facility at UCL and used at a MOI of 10. Lentivirus for NT5C cDNA was packaged in 
HEK293T cells by FuGENE transfection. Lentiviral plasmid, packaging plasmid (p8.91) and coat protein plasmid 
(pMDG) were used at a 1.5:1:1 ratio. Viral supernatants were collected after 48 and 72 h, cleared through a 0.45 μ 
m filter and stored at − 80 °C. cDNA lentivirus was used at a 1x concentration. For production of stable cell lines, 
lentiviral transduced cells were selected with puromycin and/or blasticidin.
dNTP Quantification by UPLC-MS/MS Sample Extraction and Analysis. Intracellular nucleotide 
pools were quantified according to the previously published method for determination of intracellular gemcit-
abine triphosphate in human PBMCs65. We modified this method and validated it for the measurement of intra-
cellular NTP and dNTPs. Briefly, samples were collected in triplicate and results averaged. Cells were washed 
in PBS and re-suspended in 100 μ l PBS and 100 μ l 0.8 M perchloric acid (PCA), vortex mixed and incubated on 
ice for 30 min. After centrifugation (10,000 g, 4 °C for 10 min), 180 μ l of supernatant was transferred to a new 
tube and stored at − 80 °C. At the time of analysis, 50 μ l of 1 M NH4Ac was added to the PCA extract, and the 
solution neutralised by addition of 20 μ l of 10% NH3. Finally, 5 μ l of internal standard 8-ChloroATP (Sigma) 
and 5 μ l deionised water was added. The extract was transferred to LC-MS vials and 10 μ l was injected in to the 
UPLC-MS/MS system. LC-MS grade water, methanol, acetonitrile and formic acid were from Fisher Scientific, 
UK. Calibration standards were prepared at 0, 1, 5 and 25 μ M.
dNTP Quantification by UPLC-MS/MS Chromatography and Mass Spectrometry 
Method. Analytes were resolved using an ultra-performance liquid chromatography system (Accela UPLC, 
Thermo Scientific, UK) equipped with a Biobasic AX 5 μ m, 100 × 2.1 mm column (Thermo Electron Corporation, 
Murrieta, CA, USA) and a mobile phase consisting of a mixture of 10 mM NH4Ac in ACN/H2O (30:70 v/v), 
pH 6.0 (buffer A), and 1 mM NH4Ac in ACN/H2O (30:70 v/v), pH 10.5 (buffer B). The mobile phase gradient 
was employed, comprising: buffer A = 95% at 0–0.5 min, from 95 to 0% over 1.25 min, held at 0% for 1.75 min, 
from 0 to 95% over 0.1 min, ending with 95% for 2.9 min, all at a flow rate of 500 μ l/min. Eluting compounds of 
interest were detected using a triple stage quadrupole Vantage mass spectrometry system (Thermo Scientific, 
UK) equipped with an electrospray ion source. Samples were analyzed by Multiple Reaction Monitoring, neg-
ative ion modes at a spray voltage of 3000 V. Nitrogen was used as sheath and auxiliary gas at a flow rate of 50 
and 20 arbitrary units, respectively. Argon was used as collision gas with pressure of 1.5 mTorr. The optimum 
transitional daughter ions mass and collision energy (CE) of each analyst were as follows: ATP 506.0 → 134.1.2 
(CE, 23 V), CTP 482.0 → 159.0 (CE, 35 V), dATP 490.0 → 159.0 (CE, 37 V), dCTP 466.0 → 159.0 (CE, 28 V), 
dTTP 481.0 → 159.0 (CE, 32 V), GTP 522.0 → 159.0 (CE, 43 V), UTP 483.0 → 159.0 (CE, 27 V) and ChloroATP 
539.9 → 159.0 (CE, 43 V).
Immunofluorescence. Cells were seeded on coverslips, fixed with 3.7% formaldehyde (15 min), perme-
abilized with 0.2% Triton-100 (5 min) and blocked in 3% BSA in PBS for 1 h at room temperature. Coverslips 
were incubated with primary antibody overnight at 4 °C, washed and incubated 1 h at room temperature with 
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secondary antibodies and/or phalloidin conjugated to fluorophores. Coverslips were mounted with ProLong 
Diamond Antifade Mountant with DAPI (Molecular Probes) and imaged using a Zeiss 700 inverted microscope. 
Primary antibodies used were Flag M2 (#F3165) from Sigma; p34 (#07-227) from Millipore; Cortactin (#05-180) 
from Upstate. Alexa Fluor® 488 phalloidin (#A12379) and other Alexa Fluor- conjugated secondary antibodies 
were from Invitrogen.
Cell Spreading Assay. Cells were trypsinized, counted and seeded at 30,000 (HT1080) or 7,500 (MEFs) cells 
per well in 12-well plates pre-coated with fibronectin (5 μ g/ml). Plates were incubated for 45 min before fixing 
with 3.7% formaldehyde (15 min), washing and staining with 0.1% Crystal Violet (30 min) at room temperature. 
Experiments were seeded in duplicate or triplicate and at least 5 fields of view were imaged per genotype. Cell 
area was manually quantified using ImageJ. For HT1080 cells, areas greater than 20,000 and less than 1000 were 
removed from the analysis. For primary MEF experiments, cell areas greater than 20,000 and less than 500 were 
removed from the analysis. Significance was analysed using one-way ANOVA plus Tukey’s multiple comparison’s 
test.
Single Cell Motility Assay. HT1080 cells were seeded at 6000 cells per well in ViewPlate-96 Black plates (Perkin 
Elmer# 6005182) in triplicate or quadruplicate. The next day, cells were labeled with 0.4 μ M CellTracker™ Orange 
CMRA Dye (Invitrogen) for 30 min to allow better cell visualization. Cells were imaged on ImageXpress Micro 
XL Widefield High Content Screening System (Molecular Devices). 4 sites per well were imaged every 10 min 
for 80 time points. Motility analysis was performed using multidimensional motion analysis within MetaXpress 
software. Significance was analysed using one-way ANOVA plus Tukey’s multiple comparison’s test.
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